Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study

Journal of Clinical Oncology

Volumn 25, Issue 29, 2007, Pages 4557-4561

  Saltz, Leonard B ^a   Lenz, Heinz Josef ^b   Kindler, Hedy L ^b   Hochster, Howard S ^b   Wadler, Scott ^b   Hoff, Paulo M ^b   Kemeny, Nancy E ^b   Hollywood, Ellen M ^b   Gonen, Mithat ^b   Quinones, Marcus ^b   Morse, Meroe ^b   Chen, Helen X ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; IRINOTECAN; NARCOTIC ANALGESIC AGENT;

ACNE; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MALE; METASTASIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 35648941728     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.0949     Document Type: Article

References (12)

1. Brentjen R, Saltz L: Epidermal growth factor receptor blockade and treatment of solid tumor malignancies, in DeVita JVT, Helman S, Rosenberg SA (eds): Progress in Oncology. Boston, MA, Jones and Bartlett, 2002, pp 113-128
2. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
3. Saltz L, Rubin M, Hochster H, et al: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:3a, 2001 (abstr 7)
4. Saltz LB, Meropol NJ, Loehrer PJ, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004
5. Ferrara N: Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611, 2004
6. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
7. Jemal A, Seigel R, Ward E, et al: Cancer Statistics 2006. CA Cancer J Clin 56:106-130, 2006
8. Riedel F, Götte K, Li M, et al: EGFR antisense treatment of human HNSCC cell lines downregulates VEGF expression and endothelial cell migration. Int J Oncol 21:11-16, 2002
9. Ciardiello F, Caputo R, Branco R, et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465, 2001
10. Viloria-Petit A, Crombet T, Jothy S, et al, Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61:5090-5101, 2001
11. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23:1s, 2005 (suppl; abstr 2)
12. Amgen: Amgen discontinues Vectibix treatment in PACCE trial evaluating Vectibix as part of triple combination regimen. 2007. http://wwwext.amgen.com/ media/media_pr_detail.jsp?year=2007 &releaseID=977186